Use of alarmins as biomarkers for assessing ischemiareperfusion injury severity after solid organ transplantation

The inventors aim to assess IL-33 and HMGB1 contributions as alarmins to I/R injury following solid organ transplantation in particular liver transplantation. This study was conducted from a prospective biological collection and a clinical database of 40 liver transplant recipients in Tours hospital center. Serum IL-33 and HMGB1 levels were determined at graft reperfusion, at the end of the liver transplantation and at postoperative day 1 and 3. A post-reperfusion liver biopsy was systematic. Serum IL-33 increase is associated with: i) severe-moderate liver lesions; ii) an early allograft dysfunction; iii) a post-reperfusion syndrome occurrence; iv) a post liver transplantation acute kidney injury occurrence. Serum HMGB1 increase is associated with: i) an early allograft dysfunction; ii) a post-reperfusion syndrome occurrence. IL-33 and HMGB1 thus contribute as alarmins to I/R injury in human liver transplantation. Their serum levels are predictive of I/R injury severity and its clinical impact. Serum assay for IL-33 and HMGB1 upon graft reperfusion could be used as early biomarkers of early allograft function in solid organ transplantation, in particular in liver transplantation.

Keywords: Liver Transplant, Alarmin, Ischemia-reperfusion injury assessment, Immunoassay
Patent Application number: European Procedure (Patents) (EPA) - 16 Déc. 2020 - 20 306 584.2
Front Immunol 2021 Sep 21 Barbier L Endogenous Interleukin-33 Acts as an Alarmin in Liver Ischemia-Reperfusion and Is Associated With Injury After Human Liver Transplantation doi: 10.3389/fimmu.2021.744927. eCollection 2021.



    Business Developper
    Inserm Transfert
    Business Developer
    Patent filling date: 16-12-2020
    Rare disease: No
    Second indication: No

    You might also be interested in